Provided by Tiger Fintech (Singapore) Pte. Ltd.

Karyopharm Therapeutics

4.39
-0.2200-4.77%
Post-market: 4.600.2100+4.78%16:28 EDT
Volume:36.02K
Turnover:164.32K
Market Cap:37.93M
PE:-0.35
High:4.83
Open:4.69
Low:4.39
Close:4.61
Loading ...

Karyopharm Therapeutics Announces New Inducement Grants for Newly-Hired Employees Under Stock Incentive Plan

Reuters
·
02 Jul

Karyopharm Therapeutics Inc. Publishes Presentation on Myelofibrosis Treatment and Selinexor's Potential in Cancer Therapy

Reuters
·
05 Jun

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
03 Jun

Karyopharm Therapeutics Announces New Inducement Stock Incentive Plan with RSU Awards for New Employees

Reuters
·
03 Jun

Karyopharm Therapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
30 May

Karyopharm Therapeutics Inc. to Participate in RBC Capital Markets Global Healthcare Conference

Reuters
·
19 May

Karyopharm abstract selected for presentation at 2025 EHA meeting

TIPRANKS
·
14 May

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

Benzinga
·
14 May

Karyopharm Therapeutics Inc : Leerink Partners Cuts Target Price to $8 From $26

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
13 May

RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating

MT Newswires Live
·
13 May

Karyopharm price target adjusted to $10 from $5 at Barclays

TIPRANKS
·
13 May

Karyopharm Therapeutics Inc : RBC Cuts Target Price to $33 From $43

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Karyopharm Therapeutics Q1 EPS $(2.77) Beats $(4.16) Estimate, Sales $30.02M Miss $35.24M Estimate

Benzinga
·
13 May

BRIEF-Karyopharm Therapeutics Q1 Net Income USD -23.462 Million

Reuters
·
13 May

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis That Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Inc - Reaffirms 2025 Revenue Guidance of $140-$155 Million

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Inc - Phase 3 Sentry Trial Passes Futility Analysis, 80% Enrolled

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Inc - Exploring Alternatives to Extend Cash Runway

THOMSON REUTERS
·
13 May